type B (HBV); non-A. non-B (NAN B); and other hepatotrophic viruses such as herpes, Epstein Barr, cytomegaloand coxsackie viruses. Hepatitis B was recognized as the most prevalent of these four groups in hemodialysis units during the past decade and remains a continued source of clinical hepatitis among patients and staff. However, NANB hepatitis, which appears epidemiologically similar to HBV, has become the major cause of post transfusion hepatitis and therefore also of importance in the dialysis environment.
The rapid development of sensitive serological assays for HAV and HBV has been complicated by changes in terminology and confusion in interpreting laboratory findings, establishing a definitive diagnosis, and evaluating infectivity. Although antigen-antibody systems have not yet been defined for NANB virus(es), the diagnosis is one of exclusion based on appropriate interpretation of HAV and HBV serological results.
Infectious hepatitis or hepatitis A. primarily transmitted by the fecal-oral route, is not a major problem in the hemodialysis environment. Recent or current hepatitis A infection, as well as past infection, is now readily diagnosed serologically. Although the prevalence of antibody to hepatitis A virus (anti-HAV) is high among older patients on dialysis, the ability to quantitate the portion of anti-HAV which is of IgM class (associated with current or very recent infections) in contrast to the IgG class (associated with past infection) clarifies the individual patient's HAV status.
In contrast to the relative simplicity of the serological approach to HAV, the serological systems associated with HBV are complex. Hepatitis B virus is characterized HBeAg positive are 10 7 times more infectioSAg and HBsAg positive HBeAg negative sera. Us than A susceptible patient exposed to hepatitis monitored sequentially for the virus antigens Band sociated antibodies responds in a characteristic and as-The first detectable serum antigenic deterrn.manner.
HBsAg, marking the initial stages of viral repli~n~nt is the liver. This is rapidly followed by transiently atlo n in iably detectable HBeAg, a marker of both i nfect~n.d As discussed earlier, when the newer antigen-antibody markers (HBeAg and anti HBe) are determined, the situations above will be clarified in terms of both infectivity and resolution (assessment of chronicity). As a final precautionary note, occasional other serological patterns may emerge, especially among dialysis patients whose exposure and reexposure is unique.
In most hemodialysis units, adequate monitoring for hepatitis B among susceptibles should include monthly determinations of liver specific enzymes (SGPT, SGOTj, HBsAg, anti-HBc and quarterly assessment of anti-HBs. Centers that monitor HBsAg and anti HBs alone will miss potentially infectious patients in the core or immunologic «window» stage of disease. When subjects are shown to be persistent carriers of HBsAg (positive for six months Editorial Dialyzing the diabetic a second look
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Northwestern University Medical School Chicago, Illinois, USA Ten years ago, diabetics were usually excluded from chronic dialysis on the grounds that they had generalized multisystem disease and their prognosis was too poor. Even Kolff, a man not particularly known for his pessimism, wrote about the «sad truth» of dialyzing diabetics (1). Renal transplantation, likewise viewed with con-284 or more), serologic monitoring can be reduced to quarterly. Individuals who have developed the protective antibody, anti-HBs, need no monitoring beyond monthly enzymes and an annual assessment to confirm the expected long-term status of anti-HBs antibodies. Presently NANB hepatitis, of increasing importance in the dialysis environment, remains a diagnosis of exclusion.
Control of hepatitis in hemodialysis units involves two aspects: 1) serological assessments of susceptibility or infectiousness of individuals and minimizing risk of exposure and 2) use of prevention or prophylaxis where available. In 1982 two effective products will be available against HBV: hepatitis B immune globulin (HBIG or an appropriately high titred anti-HBs pool of normal immune globulin) and HBV inactivated (killed) vaccine, licensed in the U.S. in November 1981, and estimated for release in June 1982. Although the final recommendations about who should be vaccinated have not been published, hemodialysis patients and staff will clearly have high priority.
siderable lack of enthusiasm, was carried out only in a few patients during the 1960's and early 1970's. In 1973, however, Kjellstrand et al reported an 80% three year survival following cadaver kidney transplantation in forty patients with insulin dependent diabetes mellitus (IDDM) (2). These results, though worse than in non-diabetics, were far better than the outcome of hemodialysis in diabetics treated at other institutions, none of whom survived as long. On the basis of these results, this influential report concluded that «renal transplantation seems more successful than chronic hemodialysis in patients with end-stage diabetic nephropathy», an opinion that received widespread acceptance.
Also supporting the superiority of renal transplantation were the results published from the Lahey Clinic and Joslin Clinic Foundations on 53 diabetic patients treated in those institutions since 1972. These patients were
